Keyword: OxyContin

Purdue's Sackler family was long rumored to have profited immensely from the drugmaker's opioid sales. The newest estimate? Up to $13 billion.

On the heels of a possible $12 billion opioid lawsuit, Purdue is asking a bankruptcy court’s permission to honor $34 million in employee incentives.

Purdue Pharma has entered the first major opioid settlement, valued at up to $12 billion, according to The Washington Post.

State attorneys general aren't thrilled with a reported $10 billion to $12 billion opioid settlement offer from Purdue Pharma, the WSJ reports.

With its oral semaglutide up for FDA review, Novo Nordisk is hunting for opportunities to boost its supply chain, and it found one in North Carolina.

Prosecutors are looking for ways to hold Purdue's founding family accountable for their role in the opioid epidemic. Arizona’s AG may have found one.

Oklahoma prosecutors have already bagged two settlements in its crusade against opioid drugmakers. Now it’s taking a swing at a third in court.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.

The Sackler family directed Purdue sales tactics for OxyContin and should be held responsible, Massachusetts' AG says.